WASHINGTON--(BUSINESS WIRE)--Roche today announced results of a small study demonstrating that all patients who discontinued treatment with Peg-Intron® (peginterferon alfa-2b) and ribavirin due to adverse events within the first 12 weeks, were able to complete 12 weeks of treatment with PEGASYS® (peginterferon alfa-2a) and ribavirin. Furthermore, 92 percent of these patients were able to go on and complete a full course of treatment with PEGASYS. The data, which were presented at the 38th annual Digestive Disease Week (DDW) conference, suggest that PEGASYS may be an option for patients who prematurely discontinue treatment with Peg-Intron for tolerability reasons.
